ECSP17019103A - Alfa-glucosidasa ácida muy potente con hidratos de carbono potenciados - Google Patents
Alfa-glucosidasa ácida muy potente con hidratos de carbono potenciadosInfo
- Publication number
- ECSP17019103A ECSP17019103A ECIEPI201719103A ECPI201719103A ECSP17019103A EC SP17019103 A ECSP17019103 A EC SP17019103A EC IEPI201719103 A ECIEPI201719103 A EC IEPI201719103A EC PI201719103 A ECPI201719103 A EC PI201719103A EC SP17019103 A ECSP17019103 A EC SP17019103A
- Authority
- EC
- Ecuador
- Prior art keywords
- glucosidase
- rhgaa
- acid alpha
- enhanced carbon
- carbon hydrates
- Prior art date
Links
- 108010028144 alpha-Glucosidases Proteins 0.000 title abstract 2
- -1 CARBON HYDRATES Chemical class 0.000 title 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 229910052799 carbon Inorganic materials 0.000 title 1
- 230000003389 potentiating effect Effects 0.000 title 1
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 abstract 4
- 102000045921 human GAA Human genes 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 abstract 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 abstract 1
- 102000016679 alpha-Glucosidases Human genes 0.000 abstract 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 abstract 1
- 229930182830 galactose Natural products 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 229920001542 oligosaccharide Polymers 0.000 abstract 1
- 150000002482 oligosaccharides Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Composición de alfa glucosidasa humana recombinante (rhGAA) derivada de células CHO que contiene una composición de glicano más optimizada que consiste en una cantidad de rhGAA que contiene N-glicanos que llevan manosa-6-fosfato (M6P) o bis-M6P mayor que las rhGAAs convencionales, junto con una baja cantidad de glicanos de alto contenido en manosa no fosforilados y una baja cantidad de galactosa terminal en oligosacáridos complejos. Se describen composiciones que contienen la rhGAA y métodos de uso.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462057842P | 2014-09-30 | 2014-09-30 | |
| US201462057847P | 2014-09-30 | 2014-09-30 | |
| US201562112463P | 2015-02-05 | 2015-02-05 | |
| US201562135345P | 2015-03-19 | 2015-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP17019103A true ECSP17019103A (es) | 2017-06-30 |
Family
ID=55631441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201719103A ECSP17019103A (es) | 2014-09-30 | 2017-03-28 | Alfa-glucosidasa ácida muy potente con hidratos de carbono potenciados |
Country Status (41)
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6851964B2 (ja) | 2014-09-30 | 2021-03-31 | アミカス セラピューティックス インコーポレイテッド | 炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ |
| IL299470B2 (en) | 2015-12-30 | 2026-05-01 | Amicus Therapeutics Inc | Improved acid alpha-glucosidase for the treatment of Pompe disease |
| ES3063549T3 (en) * | 2015-12-30 | 2026-04-17 | Amicus Therapeutics Inc | Augmented acid alpha-glucosidase for the treatment of pompe disease |
| CA3019354A1 (en) | 2016-03-30 | 2017-10-05 | Amicus Therapeutics, Inc. | Method for selection of high m6p recombinant proteins |
| EP4793349A2 (en) * | 2016-03-30 | 2026-08-19 | Amicus Therapeutics, Inc. | Method for selection of high m6p recombinant proteins |
| KR102618519B1 (ko) | 2016-03-30 | 2023-12-28 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 재조합 산 알파-글루코시다제를 포함하는 제형 |
| US11357834B2 (en) | 2017-01-10 | 2022-06-14 | Amicus Therapeutics, Inc. | Recombinant α-galactosidase A for treatment of Fabry disease |
| EA039750B1 (ru) * | 2017-03-30 | 2022-03-10 | Амикус Терапьютикс, Инк. | Способ отбора рекомбинантных белков с высоким содержанием m6p |
| CN119113091A (zh) * | 2017-05-15 | 2024-12-13 | 阿米库斯治疗学公司 | 重组人类酸性α-葡萄糖苷酶 |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| BR112022004000A2 (pt) | 2019-09-06 | 2022-05-31 | Amicus Therapeutics Inc | Método para captura e purificação de biológicas |
| JP2024506346A (ja) * | 2021-02-11 | 2024-02-13 | アミカス セラピューティックス インコーポレイテッド | 組換えヒト酸性アルファグルコシダーゼ及びその使用 |
| AU2022246021A1 (en) * | 2021-03-23 | 2023-10-05 | Glycoera Ag | Glycan-mediated protein degradation |
| WO2023150387A1 (en) * | 2022-02-07 | 2023-08-10 | M6P Therapeutics, Inc. | Compositions comprising acid alpha glucosidase and methods of use thereof |
| WO2023215865A1 (en) | 2022-05-05 | 2023-11-09 | Amicus Therapeutics, Inc. | Methods for treating pompe disease |
| WO2024119091A1 (en) | 2022-12-02 | 2024-06-06 | Amicus Therapeutics, Inc. | Fexamethods for treating infantile-onset pompe disease in pediatric patients |
| AR131256A1 (es) | 2022-12-02 | 2025-03-05 | Amicus Therapeutics Inc | Métodos para tratar la enfermedad de pompe de inicio tardío en pacientes pediátricos |
| WO2026006625A1 (en) | 2024-06-26 | 2026-01-02 | Amicus Therapeutics, Inc. | Miglustat formulations comprising nitrosamine for use in the treatment of pompe disease |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4837237A (en) | 1985-07-09 | 1989-06-06 | Fred Hutchinson Cancer Research Center | Therapy using glucosidase processing inhibitors |
| US5879680A (en) | 1987-12-23 | 1999-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Cloned DNA for synthesizing unique glucocerebrosidase |
| US4985445A (en) | 1988-02-12 | 1991-01-15 | Meiji Seika Kaisha, Ltd. | Cancer cell metastasis inhibitors and novel compounds |
| US5236838A (en) | 1988-12-23 | 1993-08-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| US6451600B1 (en) | 1989-12-22 | 2002-09-17 | Genzyme Corporation | Enzymatically active recombinant glucocerebrosidase |
| US5179023A (en) | 1989-03-24 | 1993-01-12 | Research Corporation Technologies, Inc. | Recombinant α-galactosidase a therapy for Fabry disease |
| US5011829A (en) | 1989-06-02 | 1991-04-30 | G. D. Searle & Co. | Pharmaceutical composition and method of inhibiting virus |
| US5103008A (en) | 1989-08-17 | 1992-04-07 | Monsanto Company | Compound, N-butyl-deoxynojirimycin-6-phosphate |
| US5401650A (en) | 1990-10-24 | 1995-03-28 | The Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of biologically active α-galactosidase A |
| US5399567A (en) | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
| US6118045A (en) | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
| US6458574B1 (en) | 1996-09-12 | 2002-10-01 | Transkaryotic Therapies, Inc. | Treatment of a α-galactosidase a deficiency |
| US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| US6210666B1 (en) | 1997-10-21 | 2001-04-03 | Orphan Medical, Inc. | Truncated α-galactosidase A to treat fabry disease |
| JP2001522833A (ja) | 1997-11-10 | 2001-11-20 | ジー・ディー・サール・アンド・カンパニー | 多剤耐性を治療するためのアルキル化イミノ糖類の使用 |
| US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| DK2020438T3 (en) | 1998-12-07 | 2018-07-23 | Genzyme Corp | Treatment of Pompe disease |
| ES2311921T3 (es) | 1999-02-12 | 2009-02-16 | United Therapeutics Corporation | N-(8,8,8-trifluorooctil)1-5,-didesoxi-1,5-imino-d-glucitol para tratar infecciones por el virus de la hepatitis. |
| JP2003505430A (ja) | 1999-07-26 | 2003-02-12 | ジー・ディー・サール・アンド・カンパニー | デオキシノジリマイシンの長鎖ｎ−アルキル誘導体およびグルコセレブロシダーゼ酵素の糖脂質異常蓄積疾患の治療用の薬剤の製造のための使用 |
| US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
| US20020095135A1 (en) | 2000-06-19 | 2002-07-18 | David Meeker | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US20040204379A1 (en) | 2000-06-19 | 2004-10-14 | Cheng Seng H. | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| US7056712B2 (en) | 2000-07-18 | 2006-06-06 | Duke University | Treatment of glycogen storage disease type II |
| CN1638739A (zh) | 2000-08-18 | 2005-07-13 | 法玛西雅厄普约翰美国公司 | 治疗成瘾性障碍的化合物 |
| US7723296B2 (en) | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
| EP1436316B1 (en) | 2001-04-30 | 2008-01-23 | ZyStor Therapeutics , Inc. | Subcellular targeting of therapeutic proteins |
| US7560424B2 (en) | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
| CN1604788B (zh) | 2001-10-16 | 2013-04-17 | 里克斯金蒂克斯公司 | 高浓度蛋白制剂及其制备方法 |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| US7658916B2 (en) | 2002-04-05 | 2010-02-09 | Genzyme Corporation | Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density |
| JP5589165B2 (ja) | 2003-01-31 | 2014-09-17 | マウント シナイ スクール オブ メディシン オブ ニューヨーク ユニバーシティー | タンパク質欠損性障害の治療のための併用療法 |
| FR2861991B1 (fr) | 2003-11-07 | 2008-01-18 | Centre Nat Rech Scient | Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose |
| US20080014188A1 (en) | 2004-02-06 | 2008-01-17 | Zankel Todd C | Manufacture of Highly Phosphorylated Lysosomal Enzymes and Uses Thereof |
| DE602005020745D1 (de) | 2004-02-10 | 2010-06-02 | Zystor Therapeutics Inc | Saure alpha-glukosidase und fragmente davon |
| US20060142234A1 (en) | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
| EP3782655A1 (en) | 2005-05-17 | 2021-02-24 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| AU2007322123A1 (en) | 2006-11-13 | 2008-05-29 | Biomarin Pharmaceutical Inc. | Methods for treating Pompe disease |
| CN101636200A (zh) * | 2006-11-13 | 2010-01-27 | 齐斯特治疗公司 | 用于治疗庞贝氏症的方法 |
| EP2155197A4 (en) | 2007-03-09 | 2011-10-12 | Link Medicine Corp | TREATMENT OF LYSOSOMAL STORAGE DISEASES |
| AU2008245578A1 (en) | 2007-04-26 | 2008-11-06 | Amicus Therapeutics, Inc. | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
| US20100317690A1 (en) | 2007-11-21 | 2010-12-16 | Summit Corporation Plc | Treatment of protein folding disorders |
| WO2009075815A1 (en) | 2007-12-07 | 2009-06-18 | Duke University | Immunomodulating gene therapy |
| WO2009102895A2 (en) | 2008-02-12 | 2009-08-20 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| AU2009223125A1 (en) | 2008-03-12 | 2009-09-17 | Amicus Therapeutics, Inc. | Assays for diagnosing and evaluating treatment options for Pompe disease |
| JP2011512876A (ja) | 2008-03-12 | 2011-04-28 | アミカス セラピューティックス インコーポレイテッド | 特異的薬理シャペロンを用いたポンペ病の治療および代理マーカーを用いた治療の監視 |
| WO2009137721A2 (en) * | 2008-05-07 | 2009-11-12 | Zystor Therapeutics, Inc. | Lysosomal targeting peptides and uses thereof |
| US20110237538A1 (en) | 2008-08-06 | 2011-09-29 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
| WO2010056746A1 (en) * | 2008-11-11 | 2010-05-20 | Amicus Therapeutics, Inc. | Therapy regimens, dosing regimens and stable medicaments for the treatment of pompe disease |
| EP3608330B1 (en) * | 2008-12-16 | 2022-11-09 | Genzyme Corporation | Synthetic intermediates for preparing oligosaccharide-protein conjugates |
| WO2010096369A1 (en) * | 2009-02-18 | 2010-08-26 | Amicus Therapeutics, Inc. | Mouse model for pompe disease and methods of use thereof |
| JP5645918B2 (ja) | 2009-04-09 | 2014-12-24 | アミカス セラピューティックス インコーポレイテッド | リソソーム蓄積障害の予防および／または治療方法 |
| US8785168B2 (en) | 2009-06-17 | 2014-07-22 | Biomarin Pharmaceutical Inc. | Formulations for lysosomal enzymes |
| JP5415170B2 (ja) | 2009-07-21 | 2014-02-12 | 富士フイルム株式会社 | 複眼撮像装置 |
| KR102000383B1 (ko) * | 2009-09-29 | 2019-07-15 | 유니버시테이트 젠트 | 만노스-1-포스포-6-만노스 결합의 포스포-6-만노스로의 가수분해 |
| US20130196410A1 (en) | 2010-03-05 | 2013-08-01 | Alnylam Pharmaceuticals, Inc | Compositions and methods for modifying the glycosylation pattern of a polypeptide |
| BR112013007616B1 (pt) * | 2010-09-29 | 2023-01-24 | Oxyrane Uk Limited | Métodos para retirar o cap ("uncapping") de porções de manose-1- fosfo-6-manose e desmanosilar n-glicanos fosforilados em uma glicoproteína, para direcionar uma glicoproteína para o interior de uma célula de mamífero, e para converter uma glicoproteína de uma primeira forma que não se liga substancialmente a um receptor de manose-6-fosfato em uma segunda forma que se liga substancialmente a um receptor de manose-6-fosfato em uma célula de mamífero |
| SG10201605874TA (en) | 2011-04-22 | 2016-09-29 | Genzyme Corp | Modified acid alpha glucosidase with accelerated processing |
| LT2714752T (lt) * | 2011-05-27 | 2018-03-12 | Amicus Therapeutics, Inc. | Nukreipiančių peptidų kopuliavimo ant rekombinantinių lizosominių fermentų būdai, skirti lizosominio kaupimo ligų gydymo pagerinimui |
| WO2013013017A2 (en) * | 2011-07-21 | 2013-01-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics |
| WO2013016249A2 (en) * | 2011-07-22 | 2013-01-31 | Insight Photonic Solutions, Inc. | System and method of dynamic and adaptive creation of a wavelength-continuous and prescribed wavelength versus time sweep from a laser |
| WO2013091897A1 (en) | 2011-12-22 | 2013-06-27 | Centogene Gmbh | Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol |
| KR20200032244A (ko) | 2012-03-07 | 2020-03-25 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 폼페병의 치료를 위한 고농도 알파-글루코시다제 조성물 |
| RS61598B1 (sr) | 2012-05-03 | 2021-04-29 | Amicus Therapeutics Inc | Režimi doziranja za tretman pompeove bolesti |
| US20150147309A1 (en) | 2012-06-06 | 2015-05-28 | Fondazione Telethon | Allosteric chaperones and uses thereof |
| TWI529396B (zh) | 2014-07-18 | 2016-04-11 | Mpi Corp | Probe card and its transfer circuit board and signal feed structure |
| JP6851964B2 (ja) | 2014-09-30 | 2021-03-31 | アミカス セラピューティックス インコーポレイテッド | 炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ |
-
2015
- 2015-09-30 JP JP2017516917A patent/JP6851964B2/ja active Active
- 2015-09-30 TW TW113100563A patent/TW202417620A/zh unknown
- 2015-09-30 LT LTEP23191307.0T patent/LT4273241T/lt unknown
- 2015-09-30 DK DK15845664.0T patent/DK3201320T5/da active
- 2015-09-30 KR KR1020227035610A patent/KR102741048B1/ko active Active
- 2015-09-30 CN CN202111483006.5A patent/CN114540327B/zh active Active
- 2015-09-30 SG SG10202003753PA patent/SG10202003753PA/en unknown
- 2015-09-30 SI SI201531983T patent/SI3201320T1/sl unknown
- 2015-09-30 TW TW111130023A patent/TWI843172B/zh active
- 2015-09-30 PT PT158456640T patent/PT3201320T/pt unknown
- 2015-09-30 EP EP23191307.0A patent/EP4273241B1/en active Active
- 2015-09-30 PE PE2017000507A patent/PE20170906A1/es unknown
- 2015-09-30 FI FIEP15845664.0T patent/FI3201320T3/fi active
- 2015-09-30 RS RS20250154A patent/RS66510B1/sr unknown
- 2015-09-30 RS RS20240027A patent/RS65066B1/sr unknown
- 2015-09-30 TN TN2017000082A patent/TN2017000082A1/en unknown
- 2015-09-30 CR CR20170107A patent/CR20170107A/es unknown
- 2015-09-30 AU AU2015325028A patent/AU2015325028B2/en active Active
- 2015-09-30 EP EP15845664.0A patent/EP3201320B1/en active Active
- 2015-09-30 HR HRP20250058TT patent/HRP20250058T1/hr unknown
- 2015-09-30 KR KR1020247040492A patent/KR20250004926A/ko active Pending
- 2015-09-30 US US15/515,808 patent/US10208299B2/en active Active
- 2015-09-30 SG SG11201702114TA patent/SG11201702114TA/en unknown
- 2015-09-30 PT PT231913070T patent/PT4273241T/pt unknown
- 2015-09-30 KR KR1020217030450A patent/KR102455814B1/ko active Active
- 2015-09-30 HR HRP20240041TT patent/HRP20240041T1/hr unknown
- 2015-09-30 HU HUE23191307A patent/HUE070443T2/hu unknown
- 2015-09-30 SM SM20250074T patent/SMT202500074T1/it unknown
- 2015-09-30 PL PL15845664.0T patent/PL3201320T3/pl unknown
- 2015-09-30 FI FIEP23191307.0T patent/FI4273241T3/fi active
- 2015-09-30 PL PL23191307.0T patent/PL4273241T3/pl unknown
- 2015-09-30 ES ES23191307T patent/ES3017134T3/es active Active
- 2015-09-30 MY MYPI2017000365A patent/MY186336A/en unknown
- 2015-09-30 BR BR112017005810A patent/BR112017005810A2/pt not_active Application Discontinuation
- 2015-09-30 EA EA201790724A patent/EA038986B1/ru unknown
- 2015-09-30 IL IL307587A patent/IL307587A/en unknown
- 2015-09-30 HU HUE15845664A patent/HUE064629T2/hu unknown
- 2015-09-30 CA CA3228032A patent/CA3228032A1/en active Pending
- 2015-09-30 CN CN201580052512.5A patent/CN107075468B/zh active Active
- 2015-09-30 MX MX2017003989A patent/MX388241B/es unknown
- 2015-09-30 TW TW110117728A patent/TWI789758B/zh active
- 2015-09-30 EP EP24197546.5A patent/EP4455283A3/en active Pending
- 2015-09-30 KR KR1020177011346A patent/KR102306577B1/ko active Active
- 2015-09-30 LT LTEPPCT/US2015/053252T patent/LT3201320T/lt unknown
- 2015-09-30 ES ES15845664T patent/ES2967620T3/es active Active
- 2015-09-30 SM SM20240010T patent/SMT202400010T1/it unknown
- 2015-09-30 TW TW104132345A patent/TWI760296B/zh active
- 2015-09-30 IL IL289383A patent/IL289383B2/en unknown
- 2015-09-30 WO PCT/US2015/053252 patent/WO2016054231A1/en not_active Ceased
- 2015-09-30 SI SI201532053T patent/SI4273241T1/sl unknown
- 2015-09-30 CA CA2961762A patent/CA2961762C/en active Active
- 2015-09-30 DK DK23191307.0T patent/DK4273241T3/da active
-
2017
- 2017-03-10 PH PH12017500455A patent/PH12017500455A1/en unknown
- 2017-03-14 IL IL251152A patent/IL251152B/en active IP Right Grant
- 2017-03-20 ZA ZA2017/01945A patent/ZA201701945B/en unknown
- 2017-03-20 DO DO2017000079A patent/DOP2017000079A/es unknown
- 2017-03-23 CO CONC2017/0002776A patent/CO2017002776A2/es unknown
- 2017-03-27 CL CL2017000722A patent/CL2017000722A1/es unknown
- 2017-03-27 MX MX2021014565A patent/MX2021014565A/es unknown
- 2017-03-28 SV SV2017005416A patent/SV2017005416A/es unknown
- 2017-03-28 NI NI201700039A patent/NI201700039A/es unknown
- 2017-03-28 EC ECIEPI201719103A patent/ECSP17019103A/es unknown
-
2019
- 2019-01-18 US US16/252,505 patent/US10961522B2/en active Active
- 2019-03-19 ZA ZA2019/01690A patent/ZA201901690B/en unknown
-
2020
- 2020-09-23 IL IL277529A patent/IL277529B/en unknown
- 2020-09-25 JP JP2020161470A patent/JP7225176B2/ja active Active
-
2021
- 2021-02-23 US US17/249,175 patent/US11753632B2/en active Active
-
2022
- 2022-02-04 US US17/665,179 patent/US11591583B2/en active Active
- 2022-05-24 AU AU2022203498A patent/AU2022203498B2/en active Active
-
2023
- 2023-02-08 JP JP2023017964A patent/JP7834671B2/ja active Active
- 2023-02-17 US US18/111,321 patent/US20230203465A1/en active Pending
-
2024
- 2024-01-10 CY CY20241100016T patent/CY1126544T1/el unknown
- 2024-03-22 LU LU00336C patent/LUC00336I2/en unknown
- 2024-03-28 FR FR24C1012C patent/FR24C1012I1/fr active Active
- 2024-04-02 LT LTPA2024509C patent/LTPA2024509I1/lt unknown
- 2024-04-02 HU HUS2400007C patent/HUS2400007I1/hu unknown
- 2024-04-02 CY CY2024009C patent/CY2024009I1/el unknown
- 2024-04-03 FI FIC20240010C patent/FIC20240010I1/fi unknown
-
2025
- 2025-01-17 US US19/028,827 patent/US20260015600A1/en active Pending
- 2025-02-17 AU AU2025201108A patent/AU2025201108A1/en active Pending
- 2025-05-21 FI FIC20250020C patent/FIC20250020I1/fi unknown
- 2025-05-23 NO NO2025023C patent/NO2025023I1/no unknown
- 2025-05-23 FR FR25C1019C patent/FR25C1019I1/fr active Active
- 2025-06-02 LT LTPA2025521C patent/LTPA2025521I1/lt unknown
- 2025-06-03 HU HUS2500025C patent/HUS2500025I1/hu unknown
-
2026
- 2026-03-11 JP JP2026039345A patent/JP2026120536A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201700039A (es) | Alfa-glucosidasa ácida muy potente con hidratos de carbono potenciados | |
| Ferreira et al. | Chemical features of Ganoderma polysaccharides with antioxidant, antitumor and antimicrobial activities | |
| BR112016015105A2 (pt) | Conjugados var2csa-droga | |
| MX378793B (es) | Composiciones oligosacarídicas y métodos para la producción de estas. | |
| BR112017013956A2 (pt) | proteínas de fusão de citocinas | |
| MX372829B (es) | Composiciones para el cuidado bucal y métodos de uso. | |
| BR112019006865A2 (pt) | caspases induzíveis e métodos para uso | |
| MX2010007500A (es) | Anticuerpo anti-cldn6. | |
| BR112016002067A2 (pt) | Variantes de enzimas | |
| MX2016011055A (es) | Nuevo polisacarido y usos del mismo. | |
| BR112014026755A2 (pt) | anticorpos contra claudin 18.2 úteis no diagnóstico de câncer | |
| MX387296B (es) | Proliferacion ex vivo de celulas epiteliales. | |
| BR112018075900A2 (pt) | composições para higiene bucal e métodos de uso | |
| BR112016007251A2 (pt) | método de processamento de biomassa que contém celulose | |
| MX2018008441A (es) | Glicosidos de esteviol altamente solubles. | |
| MX391924B (es) | Soluciones de glicosidos de esteviol. | |
| BR112017025322A2 (pt) | métodos integrados para tratamento de material lignocelulósico | |
| WO2016201257A3 (en) | Compositions and methods for identifying adp-ribosylated sites by mass spectrometry | |
| BR112018075975A2 (pt) | composição para higiene bucal e método de uso | |
| BR112012014865A2 (pt) | lentes de contato estabilizadas | |
| BR112019008048A2 (pt) | método para preparar rebaudiosídeo n com o uso de método enzimático | |
| BR112019007073A2 (pt) | extrato de planta embebido em alulose e método de preparação | |
| CR20160225A (es) | Glicoproteínas recombinantes y sus usos | |
| BR112022009244A2 (pt) | Complexo, composição, kit, uso de um complexo, substância antibiótica derivatizada, método para produzir uma substância antibiótica estabilizada e usos de um reagente de derivatização nucleofílica e de um antibiótico derivatizado | |
| MX2017004650A (es) | Composiciones topicas que contienen glicosaminoglicanos reticulados. |